Supplementary Figure S9 from Structural Basis for Multivalent MUC16 Recognition and Robust Anti-Pancreatic Cancer Activity of Humanized Antibody AR9.6

Fig. S9. Evaluation of huAR9.6’s potential toxicity. Liver enzyme profile showing (A) ALT and (B) AST measured in vehicle control (PBS), huIgG and huAR9.6 (500 µg/25 g bodyweight, i.p. for 4 doses) treated orthotopic PDAC tumor-bearing mice (n=5). (C) Representative H&E staining of liver, lung, spleen, and kidney collected from the vehicle control (PBS), huIgG and huAR9.6-treated orthotopic PDAC tumor-bearing mice (n=7) on day 28. (D) Schematic of a single-dose toxicity model in athymic nude mice (n=6). Blood collection was done on day 0 (pre-treatment), after which mice were treated with a single dose of vehicle (PBS) or huAR9.6 (1 mg/25 g bodyweight, i.p.), followed by blood collection on days 3 and 14. Body weight measurements were done daily. At the experimental endpoint (day 14), mice were euthanized. (E) Body weight measurements in grams (g) for mice treated with single-dose vehicle (PBS) or huAR9.6 (1 mg/mL). Day 0 serves as the pre-treatment timepoint. Liver enzyme profile showing (F) ALT and (G) AST measured in serum at pre-treated, 3- and 14-days post treatment timepoints. (H) Representative H&E staining of pancreas, liver, lung, spleen, and kidney collected from mice 14 days after single-dose treatment with vehicle or huAR9.6 (1 mg/mL).